Does Wellcare Cover Mounjaro?
The verdict
Conditional on most plans
Wellcare (Centene) covers Mounjaro for type 2 diabetes under Medicare Part D and Medicaid with prior authorization. Wellcare guidance explicitly excludes weight-loss GLP-1 use. Mounjaro is not in the 2026 Medicare GLP-1 Bridge. The weight-loss tirzepatide is Zepbound, with separate coverage. The Lilly savings card is not available to Medicare Part D or Medicaid beneficiaries. Verify tier and copay on your Wellcare plan drug list.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Wellcare using your member ID.
Key facts
Wellcare (Centene) guidance explicitly excludes weight-loss GLP-1 use. Mounjaro is covered for type 2 diabetes only under Part D and Medicaid, with prior authorization.
Wellcare (Centene), plan drug list and coverage guidance, 2025-2026
The 2026 Medicare Part D out-of-pocket cap is $2,100. Most Wellcare Part D enrollees on continuous Mounjaro for T2D reach it within 2-3 months and pay $0 for the rest of the year.
CMS.gov, Medicare Part D Redesign 2025-2026
The IRA-negotiated Medicare MFN price for tirzepatide (Mounjaro) is $245/month, effective mid-2026 for Medicare enrollees.
CMS.gov, IRA Drug Price Negotiation Program, 2026
Medicare vs. commercial coverage
Whether Wellcare covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Wellcare Medicare Part D plans cover Mounjaro for type 2 diabetes only — not weight loss — per the Wellcare plan drug list, with prior authorization. The 2026 Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach it within 2-3 months and pay $0 thereafter. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month, July 1, 2026 – December 31, 2027), which covers weight-loss-approved products only (Wegovy, Foundayo, Zepbound KwikPen). Wellcare guidance explicitly excludes weight-loss GLP-1 use. The Lilly savings card is not usable by Medicare or Medicare Advantage beneficiaries.
Commercial / Employer
Group & marketplace plans
Wellcare has limited commercial employer-sponsored coverage. Where available, Mounjaro is covered for T2D with PA. ACA: Centene operates Ambetter ACA plans across multiple states; Mounjaro is covered for T2D with PA where offered; weight-loss GLP-1s are commonly excluded. Medicaid: Centene operates Medicaid managed-care plans (including Wellcare-branded) across multiple states; Mounjaro is covered for T2D at nominal cost-share per state PDL with prior authorization. Weight-loss GLP-1 coverage is excluded per Wellcare guidance. The Lilly savings card is not available to Medicaid beneficiaries. Verify on your plan drug list or Wellcare member services.
The 5 boxes you must tick to get approved
Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $1,300–$1,560/month retail (WAC ~$1,080). The Lilly savings card is not available to Medicare Part D or Medicaid beneficiaries.
List price with no coverage — before any manufacturer savings card.
With coverage
Medicare Part D: 25% coinsurance after deductible until the $2,100 OOP cap 2026; most continuous users reach the cap in 2-3 months. MFN $245/month mid-2026. Medicaid: nominal cost-share per state PDL.
Typical monthly copay once prior authorization is approved.
Bridge program
The 2026 Medicare GLP-1 Bridge ($50/month) covers weight-loss-approved products only; Mounjaro is not included.
Reduced copay through the assistance program, where eligible.
All figures are estimates; actual cost-share varies by Wellcare plan and pharmacy. Confirm tier and copay on your Wellcare plan drug list or member services. The Lilly savings card applies only to commercially insured patients and expires 12/31/2026.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Check your Wellcare plan drug list for Mounjaro
Visit wellcare.com or your Wellcare member portal and use the plan drug list (formulary) for your specific Medicare Part D or Medicaid plan. Enter 'Mounjaro' or 'tirzepatide'. Confirm it is listed for type 2 diabetes (E11.x) and note whether prior authorization is required. Because Wellcare operates multiple Part D plan types (Value Script, Classic Plus, etc.) and state Medicaid MCOs, coverage details vary by plan.
- 2
Have your prescriber submit the prior authorization
Your prescriber needs to document your confirmed T2D diagnosis, A1c of 6.5% or higher, and prior oral agent step therapy. Wellcare Part D requires a coverage determination request, which your prescriber or their office submits. Allow up to 72 hours for standard review. Verify the specific PA criteria on the Wellcare plan drug list before submission.
- 3
Call Wellcare member services to confirm cost and Bridge eligibility
Call the number on the back of your Wellcare card. Ask: Is Mounjaro covered for type 2 diabetes on my plan? What is my cost-share? Am I enrolled in a plan participating in the 2026 Medicare GLP-1 Bridge, and does the Bridge cover Mounjaro? (The answer to the last question: No — Mounjaro is excluded from the Bridge because it is a diabetes drug.)
Options if Wellcare won't cover Mounjaro
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide)
FDA-approved for type 2 diabetes. Often covered with PA on Wellcare Part D and Medicaid plans for T2D; may be at a more favorable tier than Mounjaro.
Trulicity (dulaglutide)
FDA-approved for T2D. GLP-1 alternative; lower list price than Mounjaro; often preferred tier on Wellcare Medicaid and Part D plans.
Jardiance (empagliflozin)
SGLT2 inhibitor for T2D with cardiovascular benefits. Often at preferred tier on Wellcare Medicare and Medicaid formularies; may be required step therapy before GLP-1 approval.
Zepbound (tirzepatide) — weight loss only
Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management and obstructive sleep apnea — not diabetes. Included in the 2026 Medicare GLP-1 Bridge ($50/month) for weight-loss-approved products. Wellcare guidance excludes weight-loss GLP-1 use; this has separate and distinct coverage from Mounjaro. Do not substitute Mounjaro for Zepbound — they are different FDA approvals.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No. Wellcare guidance explicitly excludes weight-loss GLP-1 use. Mounjaro is FDA-approved for type 2 diabetes only; off-label weight-loss requests are denied across all Wellcare lines — Medicare Part D, Medicaid, and commercial. The weight-loss tirzepatide is Zepbound, which has separate coverage. Mounjaro is also not in the 2026 Medicare GLP-1 Bridge, which covers weight-loss-approved products only.
No. The 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027) covers weight-loss-approved products only: Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is FDA-approved for type 2 diabetes, not weight loss. Wellcare Part D covers Mounjaro for diabetes under standard Part D with prior authorization, specialty-tier cost-share, and the $2,100 annual OOP cap.
Under the 2026 Medicare Part D redesign, you pay 25% coinsurance after your deductible until you reach the $2,100 annual out-of-pocket cap. Most continuous Mounjaro users for diabetes reach the cap within 2-3 months and pay $0 for the remainder of the year. Starting mid-2026, the IRA-negotiated MFN price of $245/month takes effect for Medicare. The Lilly savings card is not available to Medicare or Medicaid beneficiaries.
Wellcare's Mounjaro PA for diabetes requires a confirmed T2D diagnosis (ICD-10 E11.x), A1c of 6.5% or higher, and prior oral agent step therapy (metformin, plus typically one additional agent). Patient must be 18 or older; quantity limit is typically 4 pens per 28 days. Note that Wellcare's exact drug-level PA criteria are not published in a primary Wellcare document at the national level — verify on your plan drug list or Wellcare member services before submission.
Centene's Wellcare-branded Medicaid MCO plans cover Mounjaro for type 2 diabetes with prior authorization and nominal cost-share per the applicable state PDL. Weight-loss GLP-1 use is excluded per Wellcare guidance. Coverage and cost-share vary by state Medicaid MCO contract — verify on your state-specific Wellcare Medicaid plan drug list or by calling member services.
Related Articles
Does Blue Cross Blue Shield of Michigan Cover Mounjaro? | Curex
BCBS of Michigan covers Mounjaro for type 2 diabetes with PA, not weight loss. Zepbound weight-loss exclusion upheld by MI DIFS in 2025.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes Blue Cross Blue Shield Cover Mounjaro? 2026 Guide | Curex
BCBS covers Mounjaro for type 2 diabetes with prior authorization — not for weight loss. The weight-loss tirzepatide is Zepbound, with separate coverage.
Read moreDoes Blue Cross Blue Shield of Arizona Cover Mounjaro? | Curex
BCBS of Arizona covers Mounjaro for type 2 diabetes with prior auth — not weight loss. AZ Medicaid covers Wegovy for weight loss, but not Mounjaro.
Read moreDoes Blue Cross Blue Shield of Texas Cover Mounjaro? 2026 | Curex
BCBS of Texas covers Mounjaro for type 2 diabetes with prior auth — not weight loss. The weight-loss tirzepatide is Zepbound, covered separately.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Mounjaro? HCSC 2026 | Curex
BCBS of Illinois (HCSC) covers Mounjaro for type 2 diabetes with PA — not weight loss. IL Medicaid covers T2D but excludes weight-loss GLP-1s.
Read moreInsurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance
Wellcare covers Mounjaro for diabetes only and excludes weight-loss GLP-1 use — and Mounjaro is not in the 2026 GLP-1 Bridge. For patients who want tirzepatide access without insurance, compounded tirzepatide from $149/mo (and compounded semaglutide from $49/mo) is available at getcurex.com/cl/glp — no insurance required, no prior authorization. This is compounded tirzepatide and is not the same medication as Mounjaro or Zepbound. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Wellcare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.